MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Abivax

< Previous 1 2 Next >
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Presents First Half 2025 Financial Results
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Closing of $747.5 Million Public Offering
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Launch of Public Offering
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Results of its June 6, 2025 Annual General Meeting
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Presents First Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Full Year 2024 Financial Results
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Publishes 2025 Financial Calendar
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces a Change to the Composition of its Board of Directors
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax presents third quarter 2024 key financial information
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
From Abivax
Via GlobeNewswire
Tickers ABVX
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
From Abivax
Via GlobeNewswire
Tickers ABVX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story